Alivus Life Sciences Limited — Important, 24-10-2024: Financial Result Updates

Glenmark Life Sciences Limited reported unaudited financial results for the second quarter and half year ending September 30, 2024. Total income reached ₹11,095.21 million, with net profit of ₹2,067.99 million. Revenue from operations was ₹10,954.95 million, and earnings per share stood at ₹16.88. The company also announced that the results were reviewed by auditors and are available on its website. A total ₹25,139.74 million was reported in other equity, showcasing positive financial health.